ArticleCell death & disease2026
FOXQ1 activates GLT8D2 to enhance CCL2 N-glycosylation and promote prostate cancer bone metastasis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Prostate cancer (PCa) is a common malignancy in men, and bone metastasis is a leading cause of mortality in advanced-stage PCa. This study aims to identify critical genes involved in PCa bone metastasis, exploring biomarkers for prognosis and precision treatment. Forkhead Box Q1 (FOXQ1) was identified as a potential key gene through screening of public databases, and was found to be markedly upregulated in bone metastatic PCa compared to primary PCa. FOXQ1 promotes PCa cell proliferation and metastasis while inhibiting apoptosis. Additionally, FOXQ1 recruits macrophages, promotes M2 polarization, and enhances osteoclast differentiation in the tumor microenvironment. Mechanistically, FOXQ1 activates the transcription of Glycosyltransferase 8 Domain Containing 2 (GLT8D2) by directly binding to its promoter, and GLT8D2 upregulates the expression of C-C Motif Chemokine Ligand 2 (CCL2) by enhancing its N-glycosylation, thereby promoting PCa bone metastasis. Collectively, these findings establish FOXQ1 as a key regulator of PCa bone metastasis through the GLT8D2/CCL2 axis, and suggest that targeting this pathway may hold therapeutic promise for bone metastatic PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.